2.70Open2.70Pre Close0 Volume18 Open Interest9.00Strike Price0.00Turnover8353.96%IV2.93%PremiumAug 16, 2024Expiry Date2.51Intrinsic Value100Multiplier-1DDays to Expiry0.19Extrinsic Value100Contract SizeAmericanOptions Type-0.6046Delta0.1013Gamma1.97Leverage Ratio-41.6024Theta0.0000Rho-1.19Eff Leverage0.0002Vega
Altimmune Stock Discussion
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
No comment yet